---
input_text: Dose-Dependent Lowering of Mutant Huntingtin Using Antisense Oligonucleotides
  in Huntington Disease Patients. On December 11 of 2017, Ionis Pharmaceuticals published
  a press release announcing dose-dependent reductions of mutant huntingtin protein
  in their HTTRx Phase 1/2a study in Huntington disease (HD) patients. The results
  from this Ionis trial have gained much attention from the patient community and
  the oligonucleotide therapeutics field, since it is the first trial targeting the
  cause of HD, namely the mutant huntingtin protein, using antisense oligonucleotides
  (ASOs). The press release also states that the primary endpoints of the study (safety
  and tolerability) were met, but does not contain data. This news follows the approval
  of another therapeutic ASO nusinersen (trade name Spinraza) for a neurological disease,
  spinal muscular atrophy, by the U.S. Food and Drug Administration and European Medicines
  Agency, in 2016 and 2017, respectively. Combined, this offers hope for the development
  of the HTTRx therapy for HD patients.
raw_completion_output: |-
  primary_disease: Huntington disease

  medical_actions: Dose-dependent lowering of mutant huntingtin using antisense oligonucleotides; approval of therapeutic antisense oligonucleotide nusinersen

  symptoms: N/A

  chemicals: Antisense oligonucleotides; nusinersen

  action_annotation_relationships: Dose-dependent lowering of mutant huntingtin using antisense oligonucleotides TREATS mutant huntingtin protein IN Huntington disease; approval of therapeutic antisense oligonucleotide nusinersen PREVENTS symptoms IN spinal muscular atrophy
prompt: |+
  From the text below, extract the following entities in the following format:

  subject_extension: <A chemical or drug mentioned in the relationship between the medical action and the symptom, for example, "analgesic agent therapy" has the aspect "analgesic">
  object_extension: <An optional term describing some specific aspect of the object, e.g. "analgesic agent therapy" has the aspect "analgesic">
  subject: <The medical action. For example: blood transfusion, radiation therapy, cardiac catheterization, pulse oximetry, otoscopy>
  predicate: <The relationship type between the medical action and the symptom, usually TREATS or PREVENTS.>
  object: <A sign or symptom associated with the disease and targeted by the medical action. For example, Low serum calcitriol, hypoplasia of the thymus, chronic cough, aortic stiffness, low pulse pressure>
  qualifier: <The primary disease the relationship is about, or specifically the disease the symptom is related to. For example, Beck-Fahrner syndrome, hereditary retinoblastoma, progeria, diabetes mellitus, infectious otitis media>
  subject_qualifier: <An optional qualifier or modifier for the subject of the statement, e.g. "high dose" or "intravenously administered">
  object_qualifier: <An optional qualifier or modifier for the object of the statement, e.g. "severe" or "with additional complications">


  Text:
  approval of therapeutic antisense oligonucleotide nusinersen PREVENTS symptoms IN spinal muscular atrophy

  ===

extracted_object:
  primary_disease: MONDO:0007739
  medical_actions:
    - Dose-dependent lowering of mutant huntingtin using antisense oligonucleotides
    - approval of therapeutic antisense oligonucleotide nusinersen
  symptoms:
    - N/A
  chemicals:
    - CHEBI:76720
    - nusinersen
  action_annotation_relationships:
    - subject: Dose-dependent lowering of mutant huntingtin
      predicate: TREATS
      object: mutant huntingtin protein
      qualifier: MONDO:0007739
      subject_extension: CHEBI:76720
    - subject: approval of therapeutic
      predicate: PREVENTS
      object: symptoms
      qualifier: MONDO:0001516
      subject_extension: CHEBI:76720
named_entities:
  - id: MONDO:0007739
    label: Huntington disease
  - id: MAXO:0001298
    label: therapy
  - id: HP:0002180
    label: neurodegeneration
  - id: HP:0001268
    label: cognitive decline
  - id: HP:0100022
    label: movement disorders
  - id: HP:0002072
    label: choreic movements
  - id: MAXO:0009003
    label: preimplantation genetic testing
  - id: MAXO:0001592
    label: RNA interference therapy
  - id: HP:0000716
    label: depression
  - id: HP:0000739
    label: anxiety
  - id: HP:0000737
    label: irritability
  - id: CHEBI:7735
    label: olanzapine
  - id: MAXO:0000882
    label: behavioral interventions
  - id: HP:0004395
    label: malnutrition
  - id: MAXO:0000011
    label: physical therapy
  - id: CHEBI:22720
    label: benzodiazepines
  - id: CHEBI:2618
    label: amantadine
  - id: CHEBI:15765
    label: levodopa
  - id: HP:0002315
    label: Headache
  - id: CHEBI:134738
    label: Laquinimod
  - id: CHEBI:4903
    label: Ethinylestradiol
  - id: CHEBI:6443
    label: Levonorgestrel
  - id: HP:0001251
    label: Ataxia
  - id: HP:0001260
    label: Dysarthria
  - id: HP:0002119
    label: Ventricular dilatation
  - id: HP:0100543
    label: cognitive deficits
  - id: HP:0000708
    label: Behavioral changes
  - id: CHEBI:92976
    label: Latrepirdine
  - id: MONDO:0005559
    label: Neurodegenerative diseases
  - id: CHEBI:16243
    label: Quercetin
  - id: CHEBI:3962
    label: Curcumin
  - id: CHEBI:27881
    label: Resveratrol
  - id: CHEBI:75095
    label: Chrysin
  - id: CHEBI:28821
    label: Piperine
  - id: CHEBI:17620
    label: Ferulic acid
  - id: CHEBI:78330
    label: Huperzine A
  - id: CHEBI:16118
    label: Berberine
  - id: CHEBI:2979
    label: Baicalein
  - id: CHEBI:28230
    label: Hesperetin
  - id: CHEBI:26536
    label: Retinoic acid
  - id: MAXO:0000127
    label: Genetic testing
  - id: CHEBI:76004
    label: Dimethyl fumarate
  - id: MAXO:0010012
    label: coenzyme Q10 supplementation
  - id: HP:0003287
    label: mitochondrial dysfunction
  - id: HP:0025464
    label: oxidative stress
  - id: CHEBI:46245
    label: coenzyme Q10
  - id: CHEBI:31687
    label: idebenone
  - id: MONDO:0100339
    label: Friedreich ataxia
  - id: MONDO:0016621
    label: Juvenile Huntington Disease
  - id: MAXO:0000021
    label: Palliative care
  - id: CHEBI:6030
    label: Isoniazid (INH)
  - id: CHEBI:16865
    label: gamma-aminobutyric acid (GABA)
  - id: HP:0000709
    label: psychosis
  - id: HP:0011951
    label: aspiration pneumonia
  - id: MAXO:0000065
    label: aerobic exercises
  - id: MAXO:0000487
    label: clinical assessments
  - id: MAXO:0000387
    label: muscle biopsy
  - id: CHEBI:9467
    label: Tetrabenazine
  - id: MAXO:0000943
    label: Deep brain stimulation
  - id: HP:0001332
    label: Dystonia
  - id: HP:0001336
    label: Myoclonus
  - id: HP:0100033
    label: Tics
  - id: HP:0001300
    label: Parkinsonism
  - id: CHEBI:35469
    label: Antidepressants
  - id: CHEBI:51373
    label: GABA agonists
  - id: CHEBI:38462
    label: Acetylcholinesterase inhibitors
  - id: MONDO:0005071
    label: Neurological disorders
  - id: MAXO:0001001
    label: Gene therapy
  - id: HP:0033429
    label: neuroinflammation
  - id: MAXO:0000079
    label: genetic counseling
  - id: MAXO:0000016
    label: Cell Therapy
  - id: MONDO:0008199
    label: Parkinson Disease (PD) and Huntington Disease (HD)
  - id: MONDO:0005314
    label: Relapsing-remitting multiple sclerosis (RRMS)
  - id: MAXO:0001394
    label: oral administration
  - id: MAXO:0001610
    label: repetitive transcranial magnetic stimulation (rTMS)
  - id: CHEBI:76720
    label: Antisense oligonucleotides
  - id: MONDO:0001516
    label: spinal muscular atrophy
